Shenzhen Kangtai Biological Products Future Growth
Future criteria checks 5/6
Shenzhen Kangtai Biological Products is forecast to grow earnings and revenue by 39.8% and 24.6% per annum respectively. EPS is expected to grow by 41% per annum. Return on equity is forecast to be 10.6% in 3 years.
Key information
39.8%
Earnings growth rate
41.0%
EPS growth rate
| Biotechs earnings growth | 43.6% |
| Revenue growth rate | 24.6% |
| Future return on equity | 10.6% |
| Analyst coverage | Good |
| Last updated | 13 Nov 2024 |
Recent future growth updates
Recent updates
Investors Appear Satisfied With Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Prospects As Shares Rocket 32%
Oct 13
Here's Why Shenzhen Kangtai Biological Products (SZSE:300601) Has A Meaningful Debt Burden
Sep 25These Analysts Just Made A Massive Downgrade To Their Shenzhen Kangtai Biological Products Co., Ltd. (SZSE:300601) EPS Forecasts
Sep 02Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Share Price Not Quite Adding Up
Aug 13Shenzhen Kangtai Biological Products (SZSE:300601) Seems To Use Debt Quite Sensibly
May 25Shenzhen Kangtai Biological Products' (SZSE:300601) Promising Earnings May Rest On Soft Foundations
May 03Earnings Report: Shenzhen Kangtai Biological Products Co., Ltd. Missed Revenue Estimates By 49%
May 01Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Share Price Matching Investor Opinion
Feb 27Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 5,136 | 1,274 | 1,269 | 1,285 | 8 |
| 12/31/2025 | 4,534 | 1,171 | 676 | 1,472 | 9 |
| 12/31/2024 | 3,167 | 628 | 525 | 949 | 4 |
| 9/30/2024 | 3,031 | 515 | 75 | 644 | N/A |
| 6/30/2024 | 2,949 | 516 | 133 | 751 | N/A |
| 3/31/2024 | 3,181 | 710 | 128 | 828 | N/A |
| 12/31/2023 | 3,477 | 861 | 315 | 1,033 | N/A |
| 9/30/2023 | 3,057 | 361 | 121 | 911 | N/A |
| 6/30/2023 | 3,060 | 257 | -112 | 777 | N/A |
| 3/31/2023 | 3,034 | -201 | -326 | 735 | N/A |
| 1/1/2023 | 3,157 | -133 | -765 | 546 | N/A |
| 9/30/2022 | 3,840 | 430 | -1,062 | 953 | N/A |
| 6/30/2022 | 4,428 | 1,047 | -749 | 1,711 | N/A |
| 3/31/2022 | 4,247 | 1,512 | -831 | 1,770 | N/A |
| 1/1/2022 | 3,652 | 1,263 | -888 | 1,652 | N/A |
| 9/30/2021 | 3,218 | 1,282 | -1,349 | 891 | N/A |
| 6/30/2021 | 2,443 | 756 | -1,361 | 463 | N/A |
| 3/31/2021 | 2,361 | 702 | -1,219 | 337 | N/A |
| 12/31/2020 | 2,261 | 679 | -787 | 440 | N/A |
| 9/30/2020 | 1,969 | 577 | 78 | 746 | N/A |
| 6/30/2020 | 2,006 | 576 | -35 | 407 | N/A |
| 3/31/2020 | 1,779 | 477 | 155 | 441 | N/A |
| 12/31/2019 | 1,943 | 575 | 119 | 506 | N/A |
| 9/30/2019 | 1,911 | 490 | 82 | 446 | N/A |
| 6/30/2019 | 1,761 | 407 | -23 | 387 | N/A |
| 3/31/2019 | 1,955 | 426 | -114 | 325 | N/A |
| 12/31/2018 | 2,017 | 436 | -7 | 336 | N/A |
| 9/30/2018 | 1,867 | 435 | -32 | 281 | N/A |
| 6/30/2018 | 1,756 | 431 | N/A | 277 | N/A |
| 3/31/2018 | 1,418 | 296 | N/A | 202 | N/A |
| 12/31/2017 | 1,161 | 215 | N/A | 154 | N/A |
| 9/30/2017 | 1,006 | 168 | N/A | 99 | N/A |
| 6/30/2017 | 816 | 101 | N/A | 35 | N/A |
| 3/31/2017 | 552 | 52 | N/A | 41 | N/A |
| 12/31/2016 | 552 | 86 | N/A | 78 | N/A |
| 9/30/2016 | 460 | 86 | N/A | 165 | N/A |
| 12/31/2015 | 453 | 63 | N/A | 278 | N/A |
| 12/31/2014 | 303 | 31 | N/A | 112 | N/A |
| 12/31/2013 | 251 | 2 | N/A | 26 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 300601's forecast earnings growth (39.8% per year) is above the savings rate (2.8%).
Earnings vs Market: 300601's earnings (39.8% per year) are forecast to grow faster than the CN market (26% per year).
High Growth Earnings: 300601's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 300601's revenue (24.6% per year) is forecast to grow faster than the CN market (13.9% per year).
High Growth Revenue: 300601's revenue (24.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 300601's Return on Equity is forecast to be low in 3 years time (10.6%).